167 related articles for article (PubMed ID: 37005587)
1. Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer.
Bulamu NB; Mpundu-Kaambwa C; O'Callaghan M; Kaambwa B
BMC Cancer; 2023 Apr; 23(1):297. PubMed ID: 37005587
[TBL] [Abstract][Full Text] [Related]
2. Suitability of the Epworth Sleepiness Scale (ESS) for Economic Evaluation: An Assessment of Its Convergent and Discriminant Validity.
Kaambwa B; Mpundu-Kaambwa C; Adams R; Appleton S; Martin S; Wittert G
Behav Sleep Med; 2018; 16(5):448-470. PubMed ID: 27754703
[TBL] [Abstract][Full Text] [Related]
3. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
[TBL] [Abstract][Full Text] [Related]
4. Construct validity of the Assessment of Quality of Life - 6D (AQoL-6D) in community samples.
Allen J; Inder KJ; Lewin TJ; Attia JR; Kelly BJ
Health Qual Life Outcomes; 2013 Apr; 11():61. PubMed ID: 23590808
[TBL] [Abstract][Full Text] [Related]
5. Psychometric Performance of the SF-6D Quality of Life Measure in an Outpatient Population with Bipolar Disorder.
Pogue YZ; Lavelle TA; Hodgkin D; Sylvia L; Ritter G; Nierenberg A
J Ment Health Policy Econ; 2022 Dec; 25(4):143-150. PubMed ID: 36535912
[TBL] [Abstract][Full Text] [Related]
6. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
[TBL] [Abstract][Full Text] [Related]
7. A review of the psychometric properties of generic utility measures in multiple sclerosis.
Kuspinar A; Mayo NE
Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the measurement properties of the AQoL and SF-6D in critical illness.
Skinner EH; Denehy L; Warrillow S; Hawthorne G
Crit Care Resusc; 2013 Sep; 15(3):205-12. PubMed ID: 23944207
[TBL] [Abstract][Full Text] [Related]
9. Translation, Cultural Adaptation, and Validation of Short-Form 6D on the General Population in Indonesia.
Andayani TM; Kristina SA; Endarti D; Haris RNH; Rahmawati A
Value Health Reg Issues; 2020 May; 21():205-210. PubMed ID: 32299053
[TBL] [Abstract][Full Text] [Related]
10. A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain.
Ye Z; Sun L; Wang Q
Health Qual Life Outcomes; 2019 Apr; 17(1):57. PubMed ID: 30971265
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population.
McDool E; Mukuria C; Brazier J
Pharmacoeconomics; 2021 Aug; 39(8):929-940. PubMed ID: 34043147
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness and minimally important difference of SF-6D and EQ-5D utility scores for the treatment of pelvic organ prolapse.
Harvie HS; Honeycutt AA; Neuwahl SJ; Barber MD; Richter HE; Visco AG; Sung VW; Shepherd JP; Rogers RG; Jakus-Waldman S; Mazloomdoost D;
Am J Obstet Gynecol; 2019 Mar; 220(3):265.e1-265.e11. PubMed ID: 30471259
[TBL] [Abstract][Full Text] [Related]
13. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
14. Assessing the validity and responsiveness of a generic preference quality of life measure in the context of posttraumatic stress disorder.
Matthews SR; Elizabeth M; Roberts LN; Kaambwa B; Wade TD; Nixon RDV
Qual Life Res; 2023 Oct; 32(10):2817-2827. PubMed ID: 37179519
[TBL] [Abstract][Full Text] [Related]
15. Validity of the Assessment of Quality of Life (AQoL) utility instrument in patients with operable and inoperable lung cancer.
Manser RL; Wright G; Byrnes G; Hart D; Conron M; Carter R; McLachlan SA; Campbell DA
Lung Cancer; 2006 Aug; 53(2):217-29. PubMed ID: 16765475
[TBL] [Abstract][Full Text] [Related]
16. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
17. Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain.
Obradovic M; Lal A; Liedgens H
Health Qual Life Outcomes; 2013 Jul; 11():110. PubMed ID: 23815777
[TBL] [Abstract][Full Text] [Related]
18. A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population.
Kangwanrattanakul K
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):765-774. PubMed ID: 32981380
[TBL] [Abstract][Full Text] [Related]
19. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
Cheung PWH; Wong CKH; Cheung JPY
Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
[TBL] [Abstract][Full Text] [Related]
20. Comparing multi-attribute utility instruments: CP-6D, a Cerebral palsy specific instrument, vs AQoL-4D.
Bahrampour M; Downes M; Scuffham PA; Byrnes J
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):217-224. PubMed ID: 33779449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
